Amiloidózis: nyitott vizsgálatok itt: Hollandia
17 trials · From ClinicalTrials.gov, checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Where
- Groningen, Maastricht, Rotterdam, Utrecht
- Age
- 18 év to 90 év
- People
- 1200 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT06128629EU 2023-507220-23-00Regiszter frissítve: 2026-11-04
1. fázisToborozTrial-stage medicine
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Amsterdam, Groningen, Utrecht
- Age
- 18 év and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335EU 2023-503679-12-00Regiszter frissítve: 2026-11-03
3. fázisCsak meghívásosTrial-stage medicine
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Groningen, Maastricht, Utrecht
- Age
- 18 év and over
- People
- 700 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT06679946Regiszter frissítve: 2026-10-21
3. fázisToborozTrial-stage medicine
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- Groningen, Maastricht, Rotterdam, Utrecht
- Age
- 18 év and over
- People
- 1280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811Regiszter frissítve: 2026-10-21
3. fázisToborozTrial-stage medicine
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Eindhoven, Groningen, Maastricht, Rotterdam, Utrecht
- Age
- 18 év to 85 év
- People
- 1750 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903EU 2024-519917-72-00Regiszter frissítve: 2026-10-20
No phaseToborozResearch participation
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
- Where
- Groningen
- People
- 1500 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT04561518Regiszter frissítve: 2026-10-13
No phaseToborozResearch participation
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
- Where
- Groningen
- People
- 10 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT05040373Regiszter frissítve: 2026-10-08
1. fázisToborozTrial-stage medicine
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Where
- Amsterdam, Groningen, Utrecht
- Age
- 18 év and over
- People
- 276 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06768489EU 2024-515316-44-00Regiszter frissítve: 2026-09-25
3. fázisToborzás még nem indultTrial-stage medicine
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- Groningen, Maastricht, Rotterdam, Utrecht
- People
- 1180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483EU 2026-526755-57-00Regiszter frissítve: 2026-08-28
1/2. fázisToborozTrial-stage medicine
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
- Age
- 18 év and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780EU 2023-507809-34-00Regiszter frissítve: 2026-08-18
3. fázisToborzás még nem indultTrial-stage medicine
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
- Where
- Groningen, Maastricht, Rotterdam, Utrecht
- Age
- 18 év and over
- People
- 250 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473EU 2024-513676-18-00Regiszter frissítve: 2026-08-11
3. fázisToborozTrial-stage medicine
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- Groningen, Maastricht, Rotterdam, Utrecht
- Age
- 18 év to 75 év
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895EU 2024-513547-82-00Regiszter frissítve: 2026-08-04
No phaseToborozResearch participation
Quantitative-imaging in Cardiac Transthyretin Amyloidosis
- Where
- Groningen
- Age
- 40 év and over
- People
- 140
- Run by
- University of Edinburgh
See details and how to joinNCT05776212Regiszter frissítve: 2026-06-26
No phaseToborozResearch participation
A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
- Where
- Utrecht
- Age
- 18 év to 99 év
- People
- 400 worldwide
- Run by
- Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT06205953Regiszter frissítve: 2026-04-16
1. fázisToborozTrial-stage medicine
A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.
- Where
- Groningen
- Age
- 60 év and over
- People
- 14
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07448623EU 2024-519372-22-00Regiszter frissítve: 2026-04-13
No phaseToborozResearch participation
International Cardiac Amyloidosis Registry
- Where
- Leiden
- Age
- 18 év and over
- People
- 300 worldwide
- Run by
- Leiden University Medical Center
See details and how to joinNCT06894290Regiszter frissítve: 2025-03-25
No phaseToborozResearch participation
A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.
- Where
- Utrecht
- Age
- 18 év and over
- People
- 600 worldwide
- Run by
- Medical University of Vienna
See details and how to joinNCT06836011Regiszter frissítve: 2025-02-19
Minden vizsgálat (Amiloidózis) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.